Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) EV/Sales Ratio: 3.12x

Is Bristol-Myers Squibb Company’s EV/Sales ratio high or low?

Bristol-Myers Squibb Company's EV/Sales ratio of 3.12x is 10% below its 5-year average of 3.47x, near the low end of its 5-year range (2.62x–4.46x).

As of Thursday, June 11, 2026. 4.48% above its 12-month average of 2.99x.

BMY EV/Sales Ratio Chart

BMY EV/Sales Ratio
3.12x+4.35% 1Y
Zoom

BMY Average EV/Sales Ratio Chart

BMY Current vs Average EV/Sales Ratio Chart

BMY EV/Sales Ratio Metrics

EV/SALES RATIO

3.12x

EV/SALES RATIO AVG TTM

2.99x

EV/SALES RATIO AVG 3Y

3.12x

EV/SALES RATIO AVG 5Y

3.47x

EV/SALES RATIO AVG 10Y

4.06x

EV/SALES RATIO AVG 15Y

4.34x

EV/SALES RATIO AVG 20Y

3.91x

CURRENT VS TTM AVG

+4.48%

CURRENT VS 3Y AVG

+0.00%

CURRENT VS 5Y AVG

-10.22%

CURRENT VS 10Y AVG

-23.10%

CURRENT VS 15Y AVG

-28.16%

CURRENT VS 20Y AVG

-20.13%

BMY Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Bristol-Myers Squibb Company (BMY)$116.13B3.12x2.99x3.12x3.47x
Vertex Pharmaceuticals Incorporated (VRTX)$110.59B8.91x9.43x10.00x9.07x
Danaher Corporation (DHR)$126.39B5.79x6.63x7.16x7.00x
CVS Health Corporation (CVS)$126.70B0.48x0.44x0.43x0.51x
Medtronic plc (MDT)$102.72B3.44x4.21x4.19x4.55x
Intuitive Surgical, Inc. (ISRG)$144.79B13.82x18.43x19.52x18.69x
Elevance Health Inc. (ELV)$86.47B0.56x0.51x0.67x0.76x
Pfizer Inc. (PFE)$149.61B3.37x3.30x3.43x3.63x
Cigna Corporation (CI)$77.92B0.37x0.38x0.50x0.55x
Abbott Laboratories (ABT)$155.75B4.07x4.94x5.00x4.98x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Bristol-Myers Squibb Company EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company EV/Sales Ratio FAQ

What is the EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The EV/Sales ratio for BMY stock is 3.12x.
Is Bristol-Myers Squibb Company's EV/Sales ratio high or low?
Bristol-Myers Squibb Company's EV/Sales ratio of 3.12x is 10% below its 5-year average of 3.47x, near the low end of its 5-year range (2.62x–4.46x).
What is the TTM average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The TTM average EV/Sales ratio for BMY stock is 2.99x.
What is the 3Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The 3Y average EV/Sales ratio for BMY stock is 3.12x.
What is the 5Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The 5Y average EV/Sales ratio for BMY stock is 3.47x.
What is the 10Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The 10Y average EV/Sales ratio for BMY stock is 4.06x.
What is the 15Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The 15Y average EV/Sales ratio for BMY stock is 4.34x.
What is the 20Y average EV/Sales ratio for Bristol-Myers Squibb Company (BMY)?
The 20Y average EV/Sales ratio for BMY stock is 3.91x.

Bristol-Myers Squibb Company EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-113.12x
2026-06-103.06x
2026-06-093.10x
2026-06-083.06x
2026-06-053.13x
2026-06-043.11x
2026-06-033.03x
2026-06-023.02x
2026-06-013.04x
2026-05-293.13x
2026-05-283.12x
2026-05-273.14x
2026-05-263.17x
2026-05-223.23x
2026-05-213.23x
2026-05-203.19x
2026-05-193.18x
2026-05-183.14x
2026-05-153.12x
2026-05-143.11x
2026-05-133.10x
2026-05-123.10x
2026-05-113.07x
2026-05-083.09x
2026-05-073.09x
2026-05-063.10x
2026-05-053.12x
2026-05-043.14x
2026-05-013.17x
2026-04-303.27x
2026-04-293.21x
2026-04-283.23x
2026-04-273.21x
2026-04-243.25x
2026-04-233.27x
2026-04-223.26x
2026-04-213.28x
2026-04-203.27x
2026-04-173.31x
2026-04-163.26x
2026-04-153.22x
2026-04-143.23x
2026-04-133.23x
2026-04-103.25x
2026-04-093.28x
2026-04-083.27x
2026-04-073.21x
2026-04-063.28x
2026-04-023.29x
2026-04-013.38x
2026-03-313.33x
2026-03-303.30x
2026-03-273.25x
2026-03-263.28x
2026-03-253.26x
2026-03-243.20x
2026-03-233.18x
2026-03-203.20x
2026-03-193.23x
2026-03-183.28x
2026-03-173.29x
2026-03-163.29x
2026-03-133.27x
2026-03-123.26x
2026-03-113.31x
2026-03-103.31x
2026-03-093.33x
2026-03-063.32x
2026-03-053.34x
2026-03-043.41x
2026-03-033.36x
2026-03-023.41x
2026-02-273.41x
2026-02-263.35x
2026-02-253.36x
2026-02-243.38x
2026-02-233.36x
2026-02-203.34x
2026-02-193.32x
2026-02-183.30x
2026-02-173.32x
2026-02-133.34x
2026-02-123.30x
2026-02-113.30x
2026-02-103.32x
2026-02-093.31x
2026-02-063.37x
2026-02-053.26x
2026-02-043.18x
2026-02-033.11x
2026-02-023.11x
2026-01-303.07x
2026-01-293.04x
2026-01-283.05x
2026-01-273.09x
2026-01-263.05x
2026-01-233.05x
2026-01-223.07x
2026-01-213.05x
2026-01-203.04x
2026-01-163.08x
2026-01-153.14x
2026-01-143.15x
2026-01-133.11x
2026-01-123.10x
2026-01-093.11x
2026-01-083.11x
2026-01-073.14x
2026-01-063.04x
2026-01-052.99x
2026-01-023.00x
2025-12-313.02x
2025-12-303.04x
2025-12-293.03x
2025-12-263.05x
2025-12-243.06x
2025-12-233.04x
2025-12-223.05x
2025-12-193.03x
2025-12-183.00x
2025-12-173.01x
2025-12-163.04x
2025-12-153.04x
2025-12-122.96x
2025-12-112.91x
2025-12-102.91x
2025-12-092.88x
2025-12-082.93x
2025-12-052.95x
2025-12-042.94x
2025-12-032.90x
2025-12-022.78x
2025-12-012.82x
2025-11-282.82x
2025-11-262.82x
2025-11-252.82x
2025-11-242.76x
2025-11-212.70x
2025-11-202.68x
2025-11-192.68x
2025-11-182.73x
2025-11-172.72x
2025-11-142.71x
2025-11-132.80x
2025-11-122.82x
2025-11-112.80x
2025-11-102.74x
2025-11-072.72x
2025-11-062.71x
2025-11-052.71x
2025-11-042.67x
2025-11-032.69x
2025-10-312.69x
2025-10-302.67x
2025-10-292.62x
2025-10-282.63x
2025-10-272.66x
2025-10-242.68x
2025-10-232.68x
2025-10-222.70x
2025-10-212.71x
2025-10-202.67x
2025-10-172.67x
2025-10-162.66x
2025-10-152.67x
2025-10-142.67x
2025-10-132.66x
2025-10-102.68x
2025-10-092.71x
2025-10-082.71x
2025-10-072.71x
2025-10-062.73x
2025-10-032.75x
2025-10-022.76x
2025-10-012.83x
2025-09-302.73x
2025-09-292.69x
2025-09-262.69x
2025-09-252.66x
2025-09-242.69x
2025-09-232.72x
2025-09-222.73x
2025-09-192.73x
2025-09-182.75x
2025-09-172.78x
2025-09-162.78x
2025-09-152.78x
2025-09-122.78x
2025-09-112.83x
2025-09-102.82x
2025-09-092.82x
2025-09-082.80x
2025-09-052.82x
2025-09-042.80x
2025-09-032.83x
2025-09-022.83x
2025-08-292.82x
2025-08-282.81x
2025-08-272.84x
2025-08-262.82x
2025-08-252.82x
2025-08-222.85x
2025-08-212.87x
2025-08-202.87x
2025-08-192.87x
2025-08-182.86x
2025-08-152.87x
2025-08-142.85x
2025-08-132.85x
2025-08-122.79x
2025-08-112.77x
2025-08-082.77x
2025-08-072.74x
2025-08-062.72x
2025-08-052.76x
2025-08-042.74x
2025-08-012.69x
2025-07-312.65x
2025-07-302.81x
2025-07-292.85x
2025-07-282.88x
2025-07-252.92x
2025-07-242.94x
2025-07-232.94x
2025-07-222.90x
2025-07-212.84x
2025-07-182.87x
2025-07-172.90x
2025-07-162.86x
2025-07-152.83x
2025-07-142.87x
2025-07-112.85x
2025-07-102.92x
2025-07-092.89x
2025-07-082.86x
2025-07-072.84x
2025-07-032.85x
2025-07-022.88x
2025-07-012.88x
2025-06-302.83x
2025-06-272.83x
2025-06-262.84x
2025-06-252.84x
2025-06-242.86x
2025-06-232.85x
2025-06-202.85x
2025-06-182.85x
2025-06-172.87x
2025-06-162.93x
2025-06-132.97x
2025-06-123.01x
2025-06-112.99x
2025-06-102.98x
2025-06-092.94x
2025-06-062.92x
2025-06-052.89x
2025-06-042.90x
2025-06-032.90x
2025-06-022.93x
2025-05-302.91x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner